SAN FRANCISCO--(BUSINESS WIRE)-- Five Prime Therapeutics, Inc., a leader in innovative biologics, announced today that Julia P. Gregory, president and chief executive officer, will present at the BIO International Convention in Chicago, Illinois on Wednesday, May 5, 2010 at 3:00 p.m. Central Standard Time. Ms. Gregory will present an overview of FivePrime, discuss the company’s clinical and preclinical development programs, corporate objectives and business strategy in Room 2 of the Business Forum.
About Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. is a clinical-stage, privately-held company discovering and developing innovative protein and antibody therapeutics. FivePrime is currently in Phase I with FP-1039 for solid tumors. Using its world-class biologics discovery platform, FivePrime is building a strong product pipeline in oncology, immunology and metabolic diseases. It has built a unique suite of technologies to mine selectively the entire extracellular human proteome - the complete collection of secreted proteins and receptors - for medically relevant therapeutic protein drugs. FivePrime is collaborating with Pfizer, Inc. in the fields of oncology and diabetes. For more information, visit www.fiveprime.com.
CONTACT:
Five Prime Therapeutics, Inc.
Jennifer Pratt Mead, 415-365-5663
[email protected]
Stephanie Andrade, 415-365-5719
[email protected]
KEYWORDS: United States North America California Illinois
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials
MEDIA:
| Logo |